Regulatory compliance – Page 39

Incomplete validation lifecycle during lifecycle management – CAPA and revalidation strategy

Managing Incomplete Validation Lifecycles in Pharmaceutical Operations Incomplete validation lifecycles can pose significant risks to pharmaceutical manufacturing operations, leading to potential regulatory non-compliance and gaps in product quality assurance. This…

ERES controls not implemented during inspection walkthrough – risk-based ERES remediation

Handling Incomplete ERES Controls During Inspection Walkthroughs: A Comprehensive Playbook The pharmaceutical industry is under increasing scrutiny for the management of Electronic Records and Electronic Signatures (ERES). When ERES controls…

Incomplete validation lifecycle during lifecycle management – preventing repeat validation findings

Preventing Repeated Validation Findings During Lifecycle Management The pharmaceutical manufacturing landscape increasingly faces challenges stemming from an incomplete validation lifecycle during lifecycle management. As regulatory scrutiny intensifies, organizations must address…

Hybrid paper-electronic workflows uncontrolled during inspection walkthrough – 21 CFR Part 11 compliance gaps

Managing Hybrid Paper-Electronic Workflows: Tactics for Compliance During Inspections The increasing integration of hybrid paper-electronic workflows has created new challenges in regulatory compliance. Specifically, 21 CFR Part 11 requirements for…

Validation gaps identified during system upgrades – CAPA and revalidation strategy

Strategies for Addressing Validation Gaps During System Upgrades In pharmaceutical manufacturing, modernization is necessary to remain competitive and compliant. However, system upgrades can often reveal validation gaps that pose significant…

Test article accountability issue during routine studies – inspection deficiency risk analysis

Managing Test Article Accountability During Routine Studies to Mitigate Inspection Deficiencies The integrity of test article accountability in routine studies is paramount in upholding Good Laboratory Practices (GLP) compliance. Even…

ERES controls not implemented during system operation – preventing repeat Part 11 findings

Implementing Effective Controls to Prevent ERES System Operation Failures The increasing reliance on electronic records and electronic signatures (ERES) in the pharmaceutical industry underscores the importance of robust controls. ERES…

Requalification overdue during inspection readiness – inspection evidence expectations

Addressing Requalification Gaps Ahead of Inspections: Evidence Expectations and Remediation Strategies The pharmaceutical manufacturing landscape requires strict adherence to regulatory guidelines, specifically during inspections where requalification of equipment and processes…

ERES controls not implemented during system upgrade – risk-based ERES remediation

Risk-Based Remediation for Inadequate ERES Controls During System Upgrade In the rapidly evolving landscape of pharmaceutical compliance, the implementation of Electronic Records and Electronic Signatures (ERES) controls during system upgrades…

Change impact not assessed during lifecycle management – inspection evidence expectations

Understanding Change Impact During Lifecycle Management: Ensuring Compliance and Readiness for Inspections The pharmaceutical industry operates under stringent regulations and guidelines that require rigorous adherence to quality and compliance measures.…

Hybrid paper-electronic workflows uncontrolled during validation lifecycle – 21 CFR Part 11 compliance gaps

Managing Uncontrolled Hybrid Paper-Electronic Workflows During Validation Lifecycle As digital transformation accelerates within pharmaceutical manufacturing, uncontrolled hybrid paper-electronic workflows pose significant regulatory compliance risks, particularly concerning 21 CFR Part 11.…

CSV compliance weak during site expansion – regulatory deficiency risk

Managing Weak CSV Compliance During Site Expansion: A Playbook for Pharma Professionals Expanding pharmaceutical manufacturing operations poses significant challenges in computer system validation (CSV), often leading to risks of regulatory…